OPRX

OPRX

USD

OptimizeRx Corporation Common Stock

$19.200+0.300 (1.587%)

Reaalajas hind

Healthcare
Health Information Services
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$18.900

Kõrge

$19.383

Madal

$18.689

Maht

0.42M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

356.4M

Tööstusharu

Health Information Services

Riik

United States

Kauplemisstatistika

Keskmine maht

0.37M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $3.78Praegune $19.200Kõrge $22.25

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 30. okt 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

OPRX Analysis: Navigating OptimizeRx's Volatile Growth Path

Recent Price Movements

  • July-August Transition: Shares jumped 37% on August 8 (12.84→17.30) with volume 5x average
  • September Rally: Steady climb from 17.16 (Sept 2) to 20.51 (Sept 29) - 19.5% gain
  • Current Position: Trading at $20.56 (Oct 29) after hitting $22.25 weekly high
  • Pattern Alert: 3 failed attempts to hold above $22 since late September

Key Catalysts

  • October 10 Analyst Boost: JMP Securities raised target to $23 (+15% from current)
  • AI Prediction Signals:
  • Short-term projections: +1.1% (D1), +1.7% (D2), +2.5% (D3)
  • High-confidence bullish signal (81.1% AI confidence)
  • Volume Surges: 3 recent spikes (584k on Aug 28, 662k on Sept 29, 421k on Oct 24)

Strategic Considerations

Strengths

  • Explosive revenue growth (55.2% YoY)
  • Strong institutional interest (4.9x average volume days)
  • Healthcare tech positioning in growing sector

Concerns

  • Profitability challenges (Negative ROE: -8.2%)
  • Heavy debt load (24.29 Debt/Equity ratio)
  • Technical resistance at $22 level

Actionable Insights

  1. Entry Window: Current price ($20.56) near support level ($20.55)
  2. Trade Parameters:
  • Stop Loss: $18.48 (10% downside protection)
  • Take Profit: $22.50 (9.4% upside)
  • Alternative Entries: $20.64-$21.08 range
  1. Holding Strategy: 1-2 week horizon aligns with AI predictions

Final Perspective

OptimizeRx presents a high-growth opportunity tempered by financial health concerns. The combination of analyst upgrades, AI bullishness, and technical support near current levels creates a favorable risk/reward scenario for short-term traders. Long-term investors should monitor debt management and profitability improvements.

Disclaimer: This analysis references historical data and AI predictions that may not reflect future performance. Consult a financial advisor before making investment decisions. Past performance does not guarantee future results.

Seotud uudised

Analyst Upgrades

JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23

JMP Securities analyst Constantine Davides maintains OptimizeRx with a Market Outperform and raises the price target from $20 to $23.

Vaata rohkem
JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 4. nov 2025, 17:09

LangevNeutraalneTõusev

65.0% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Kasv
Kauplemisjuhend

Sisenemispunkt

$19.62

Võta kasum

$20.97

Peata kahjum

$17.52

Põhitegurid

DMI näitab langustrendi (ADX:20.6, +DI:11.5, -DI:21.0), mis viitab ettevaatlikkusele
Praegune hind on tugitasemele ($19.62) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 5.2x keskmisest (3,766), mis viitab äärmiselt tugevale ostusurvele
MACD -0.1007 on signaalijoone -0.0825 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.